NSAIDs in the treatment and/or prevention of neurological disorders

Inflammopharmacology

Volumn 20, Issue 3, 2012, Pages 159-167

  Khansari, Parto S ^a   Coyne, Leanne ^a  

^a California Northstate College of Pharmacy   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Aspirin; COX 2; Fenamates; Ibuprofen; Inflammation; Neuroprotection; Nimesulide; NSAIDs; Parkinson's disease; Stroke

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FENAMIC ACID DERIVATIVE; FENOFIBRATE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MEFENAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPOFOL; RECOMBINANT INTERLEUKIN 1ALPHA; SALICYLATE SODIUM;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; BRAIN EDEMA; BRAIN ISCHEMIA; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 84862998485     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-011-0116-2     Document Type: Review

References (90)

1. Äid S, Bosetti F (2011) Targeting cyclooxygenases-1 and-2 in neuroinflammation: therapeutic implications. Biochimie 93(1): 46-51
2. Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, Zipp F (2007) Neuronal damage in brain inflammation. Arch Neurol 64(2): 185-189
3. Aoki E, Yano R, Yokoyama H, Kato H, Araki T (2009) Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahyropyridine)-induced apop-tosis in nigral neurons of mice. Exp Mol Pathol 86(1):57-64
4. Arvin B, Neville LF, Barone FC, Feuerstein GZ (1996) The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 20(3):445-452
5. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71(4):1635-1642
6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849-1860
7. Barneoud P, Curet O (1999) Beneficial effects of lysine acetylsalic-ylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 155(2):243-251
8. Bauman S, Höttecke N, Schubenel R, Baumann K, Schmidt B (2009) NSAID-derived c-secretase modulators. Part III: membrane anchoring. Bioorg Med Chem Lett 19:6986-6990
9. Beresford IJ, Parsons AA, Hunter AJ (2003) Treatments for stroke. Expert Opin Emerg Drugs 8(1):103-122
10. Biller J (2009) Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy. J Neurol Sci 284(1-2):1-9
11. Botting RM (2010) Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 62(3):518-525
12. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82(3):615-624
13. Candelario-Jalil E (2008) Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences. Pharmacol Res 57:266-273
14. Candelario-Jalil E, Alvarez D, Merino N, León OS (2003) Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils. Neurosci Res 47(2):245-253
15. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82(1-4): 85-94
16. Castillo J, Leira R, Moro MA, Lizasoain I, Serena J, Dávalos A (2003) Neuroprotective effects of aspirin in patients with acute cerebral infarction. Neurosci Lett 339(3):248-250
17. Chae SW, Kang BY, Hwang O, Choi HJ (2008) Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells. Neurosci Lett 436(2):205-209
18. Chaturvedi RK, Beal MF (2008) PPAR: a therapeutic target in Parkinson's disease. J Neurochem 106(2):506-518
19. Chen Q, Olney JW, Lukasiewicz PD, Almli T, Romano C (1998) Fenamates protect neurons against ischemic and excitotoxic injury in chick embryo retina. Neurosci Lett 242(3):163-166
20. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58(6):963-967
21. Consilvio C, Vincent AM, Feldman EL (2004) Neuroinflammation, COX-2, and ALS-a dual role? Exp Neurol 187(1):1-10
22. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294(5545):1346-1349
23. Cookson MR, van der Brug M (2008) Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209(1):5-11
24. Coyne L, Su J, Patten D, Halliwell RF (2007) Characterization of the interaction between fenamates and hippocampal neuron GABA(A) receptors. Neurochem Int 51(6-7):440-446
25. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60(1):22-31
26. De Cristóbal J, Cárdenas A, Lizasoain I, Leza JC, Fernández-Tomé P, Lorenzo P, Moro MA (2002) Inhibition of glutamate release via recovery of ATP levels accounts for a neuroprotective effect of aspirin in rat cortical neurons exposed to oxygen-glucose deprivation. Stroke 33(1):261-267
27. De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nature Rev Neurol 6:99-108
28. Drachman DB, Rothstein JD (2000) Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 48(5):792-795
29. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLedon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE (2003) NSAIDs and enantiomers of flurbiprofen target c-secretase ad lower Ab42 in vivo. J Clin Investig 112:440-449
30. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205(2):295-312
31. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, Hong JS (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl 1,2,3,6-tetrahydropyr-idine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329(3):354-358
32. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14(15):1927-1929
33. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase II safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer's disease. Arch Neurol 65(8):1031-1038
34. Goldberg MS, Lansbury PT Jr (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2(7):E115-E119
35. Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Ab isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochimica Biophysica Acta 182-188
36. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S, Panikashvili D, Shohami E, Jansen SA, Narayan RK, Strauss KI (2005) Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 56(3):590-604
37. Grilli M, Pizzi M, Memo M, Spano P (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274(5291):1383-1385
38. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64(2):919-924
39. Hattori N, Machida Y, Sato S, Noda K, Iijima-Kitami M, Kubo S, Mizuno Y (2006) Molecular mechanisms of nigral neurodegen-eration in Park2 and regulation of parkin protein by other proteins. J Neural Transm Suppl 70:205-208
40. Hensley K, Mhatre M, Mou S, Pye QN, Stewart C, West M, Williamson KS (2006) On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal 8(11-12):2075-2087
41. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA (2000) Cyclooxy-genase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther 293(2):417-425
42. Hewett SJ, Bell SC, Hewett JA (2006) Contributions of cyclooxy-genase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacol Ther 112(2):335-357
43. Hirohata M, Ono K, Morinaga A, Yamada M (2008) Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Neuro-pharmacology 54(3):620-627
44. Huang J, Upadhyay UM, Tamargo RJ (2006) Inflammation in stroke and focal cerebral ischemia. Surg Neurol 66(3):232-245
45. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98(3):1294-1299
46. Iqbal K, Alonso AC, Chen S, Chohan MO, El-Akkad E, Gong C, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739:198-210
47. Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM (2008) Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med 14(7-8):451-464
48. Kalra S, Cashman NR, Genge A, Arnold DL (1998) Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9(8):1757-1761
49. Khansari PS, Halliwell RF (2009) Evidence for neuroprotection by the fenamate NSAID, mefenamic acid. Neurochem Int 55: 683-688
50. Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson's disease: iNOS, lipocortin 1, and cyclooxygenase-1 and-2. Mol Cell Neurosci 16(6):724-739
51. Kubo K, Inada T, Shingu K (2011) Possible role of propofol's cyclooxygenases-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease. Brain Res 1387:125-133
52. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11:545-550
53. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL (2007) Monoclonal antibodies that target pathological assemblies of Ab. J Neurochem 100:23-35
54. Lerma J, Martin del Rio R (1992) Chloride transport blockers prevent N-methyl-D-aspartate receptor-channel complex activation. Mol Pharmacol 41(2):217-222
55. Lewén A, Matz P, Chan PH (2000) Free radical pathways in CNS injury. J Neurotrauma 17(10):871-890
56. Lo EH, Dalkara T, Moskowitz MA (2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4(5):399-415
57. Lutsep HL (2009) Recent clinical trials of antiplatelet therapy in secondary stroke prevention: expectations and results for application in primary care settings. Am J Med 122(4 Suppl 2):S21-S31
58. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 18 epidemiological studies. Neurology 48:425-432
59. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008) Ibuprofen reduces Ab, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207:225-236
60. Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34(1):55-65
61. Minnerup J, Schabitz WR (2009) Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 6(1):43-52
62. Moro MA, De Alba J, Cárdenas A, De Cristóbal J, Leza JC, Lizasoain I, D́iaz-Guerra MJ, Boscá L, Lorenzo P (2000) Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose deprivation in rat forebrain slices. Neuropharmacology 39(7): 1309-1318
63. Muralikrishna Adibhatla R, Hatcher JF (2006) Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40(3):376-387
64. Nighoghossian N, Wiart M, Cakmak S, Berthezène Y, Derex L, Cho TH, Nemoz C, Chapuis F, Tisserand GL, Pialat JB, Trouillas P, Froment JC, Hermier M (2007) Inflammatory response after ischemic stroke: a USPIO-enhanced MRI study in patients. Stroke 38(2):303-307
65. Niwa K, Haensel C, Ross ME, Iadecola C (2001) Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation. Circ Res 88(6):600-608
66. Park EM, Cho BP, Volpe BT, Cruz MO, Joh TH, Cho S (2005) Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression. Neuro-science 132(3):625-631
67. Partridge LD, Valenzuela CF (2000) Block of hippocampal CAN channels by flufenamate. Brain Res 867(1-2):143-148
68. Partridge LD, Müller TH, Swandulla D (1994) Calcium-activated non-selective channels in the nervous system. Brain Res Brain Res Rev 19(3):319-325
69. Phillis JW, Horrocks LA, Farooqui AA (2006) Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 52(2): 201-243
70. Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM (2003) A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Faseb J 17(6):725-727
71. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. New Engl J Med (362):329-344
72. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y, American Heart Association Statistics Committee Stroke Statistics Subcommittee (2007) Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5):e69-e171
73. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966(2):245-252
74. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23(30):9796-9804
75. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT (2006) Nonsteroidal anti-inflammatory drugs repress b-secretase gene promoter activity by the activation of PPARc. PNAS 103:443-448
76. Small DL, Morley P, Buchan AM (1999) Biology of ischemic cerebral cell death. Prog Cardiovasc Dis 42(3):185-207
77. Strauss KI (2008) Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav Immun 22(3):285-298
78. Strauss KI, Marini AM (2002) Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death. J Neurotrauma 19(5):627-638
79. Strong MJ (2003) The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Ther 98(3):379-414
80. Stuhlmeier KM, Li H, Kao JJ (1999) Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol 57(3):313-320
81. Sweeney MI, Yager JY, Walz W, Juurlink BH (1995) Cellular mechanisms involved in brain ischemia. Can J Physiol Pharmacol 73(11):1525-1535
82. Teather LA, Packard MG, Bazan NG (2002) Post-training cycloox-ygenase-2 (COX-2) inhibition impairs memory consolidation. Learn Mem 9(1):41-47
83. Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39(2): 167-174
84. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K (2009) NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 119(12):3692-3702
85. Volles MJ, Lansbury PT Jr (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42(26):7871-7878
86. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-216
87. Wolff T, Miller T, Ko S (2009) Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Ann Intern Med, Preventive Services Task Force 150(6): 405-410
88. Yermakova A, O'Banion MK (2000) Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 6:1755-1776
89. Zhang Y, Thompson R, Zhang H, Xu H (2011) APP Processing in Alzheimer's disease. Mol Brain 4:3
90. Zinman L, Cudkowicz M (2011) Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 10(5):481-490